Pan American Health Organization is in Early Negotiations with Takeda for Affordable Dengue Vaccine Price
The Pan American Health Organization (PAHO) is in talks with Takeda Pharmaceutical Company Limited to negotiate an affordable price for its dengue vaccine. The vaccine is considered a major breakthrough in the fight against the deadly disease, which affects millions of people worldwide. This article will explore the details of the negotiations and the potential impact of an affordable dengue vaccine.
Introduction
Dengue is a mosquito-borne viral disease that affects over 100 countries worldwide, mostly in tropical and subtropical regions. It is estimated that approximately 390 million people are infected with dengue every year, leading to 25,000 deaths annually. There is currently no specific treatment for dengue, and the best way to prevent the disease is through vaccination. Takeda's dengue vaccine, known as Dengvaxia, was approved for use in several countries in 2015, but its high cost has limited its accessibility to many people.
Background
In 2015, Takeda's Dengvaxia became the first approved vaccine for dengue. The vaccine was approved in several countries, including Mexico, Brazil, and the Philippines. However, the vaccine's high cost has been a major barrier to its accessibility, particularly in low-income countries where the burden of dengue is highest. The vaccine requires three doses, and its cost can range from $100 to $200 per dose. As a result, the vaccine has been mostly used in the private sector, and few governments have included it in their vaccination programs.
Negotiations
In an effort to increase access to the dengue vaccine, PAHO has been in talks with Takeda to negotiate an affordable price for the vaccine. PAHO is a specialized international health agency that works to improve health and living standards of people in the Americas. It has played a key role in promoting vaccination programs in the region, particularly for diseases like yellow fever and measles. PAHO's negotiations with Takeda are aimed at securing a lower price for the vaccine, which could help increase its accessibility in low-income countries.
Potential Impact
An affordable dengue vaccine could have a significant impact on public health, particularly in low-income countries where the burden of dengue is highest. Dengue is a major cause of hospitalization and death, particularly among children. A vaccine that is more accessible and affordable could help reduce the burden of the disease, particularly in regions where mosquito-borne diseases are prevalent. In addition, an affordable vaccine could also lead to increased coverage in vaccination programs, which could help prevent future outbreaks of the disease.
Challenges
Negotiating an affordable price for the dengue vaccine is not without its challenges. Takeda has invested significant resources in the development of the vaccine and has a right to recoup its investment. In addition, the vaccine's price is affected by various factors, including the cost of production, distribution, and marketing. However, PAHO's negotiations with Takeda could help find a balance between the need for affordable vaccines and the need for pharmaceutical companies to recoup their investments.
Conclusion
PAHO's negotiations with Takeda to secure an affordable price for the dengue vaccine could be a major breakthrough in the fight against the disease. An affordable vaccine could help increase access to the vaccine, particularly in low-income countries where the burden of dengue is highest. However, negotiating an affordable price is not without its challenges, and finding a balance between affordable vaccines and pharmaceutical companies' need to recoup their investments is essential. With continued efforts and collaboration, an affordable dengue vaccine could become a reality, reducing the burden of dengue
0 Comments